Literature DB >> 9058295

Mutations in a hydrophilic part of the core gene of hepatitis C virus in patients with hepatocellular carcinoma in China.

I Shimizu1, D F Yao, C Horie, M Yasuda, M Shiba, T Horie, T Nishikado, X Y Meng, S Ito.   

Abstract

We investigated the association between hepatocellular carcinoma (HCC) and the genomic characteristics of the hepatitis C virus (HCV) isolated from residents of the inshore region of the Yangtze River, an area that has one of the highest incidence of HCC in China. We determined the genomic heterogeneity of HCV, and the sequence divergence of the HCV core gene in individuals with chronic hepatitis and HCC. HCV genotype II was predominant among these isolates, which were homologous to other Chinese and Japanese HCV isolates. The rate of nucleotide substitutions in the core gene was significantly greater for isolates from HCC patients than for those from individuals with chronic hepatitis. The nucleotide substitutions were unevenly scattered along the core gene; a cluster of missense mutations was apparent in the region encoding the second hydrophilic domain of the core protein. The rate of occurrence of missense mutations per nucleotide substitution was significantly greater in this clustering variable region (CVR) of the core gene than in the remaining core gene sequence. These observations suggest that mutations in the CVR may be involved in the pathogenesis of chronic HCV infection during hepatocellular carcinogenesis.

Entities:  

Mesh:

Year:  1997        PMID: 9058295     DOI: 10.1007/bf01213296

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  44 in total

1.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

2.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection.

Authors:  T Ehata; M Omata; O Yokosuka; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

Review 3.  Cytotoxic T-lymphocytes.

Authors:  M S Pasternack
Journal:  Adv Intern Med       Date:  1988

4.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

6.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Prevalence, genotypes, and an isolate (HC-C2) of hepatitis C virus in Chinese patients with liver disease.

Authors:  Y Wang; H Okamoto; F Tsuda; R Nagayama; Q M Tao; S Mishiro
Journal:  J Med Virol       Date:  1993-07       Impact factor: 2.327

8.  Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma.

Authors:  M Colombo; M G Rumi; M F Donato; M A Tommasini; E Del Ninno; G Ronchi; G Kuo; M Houghton
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

9.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma.

Authors:  R K Ross; J M Yuan; M C Yu; G N Wogan; G S Qian; J T Tu; J D Groopman; Y T Gao; B E Henderson
Journal:  Lancet       Date:  1992-04-18       Impact factor: 79.321

10.  Precore mutations and core clustering mutations in chronic hepatitis B virus infection.

Authors:  W L Chuang; M Omata; T Ehata; O Yokosuka; Y Ito; F Imazeki; S N Lu; W Y Chang; M Ohto
Journal:  Gastroenterology       Date:  1993-01       Impact factor: 22.682

View more
  6 in total

1.  Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.

Authors:  Zhi-Zhen Dong; Deng-Fu Yao; Deng-Bing Yao; Xin-Hua Wu; Wei Wu; Li-Wei Qiu; Dao-Rong Jiang; Jian-Hua Zhu; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

2.  Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions.

Authors:  José L Walewski; Julio A Gutierrez; Westyn Branch-Elliman; Decherd D Stump; Toby R Keller; Alfredo Rodriguez; Gary Benson; Andrea D Branch
Journal:  RNA       Date:  2002-05       Impact factor: 4.942

3.  Hepatitis C virus core from two different genotypes has an oncogenic potential but is not sufficient for transforming primary rat embryo fibroblasts in cooperation with the H-ras oncogene.

Authors:  J Chang; S H Yang; Y G Cho; S B Hwang; Y S Hahn; Y C Sung
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma.

Authors:  Satoshi Ogata; Motoko Nagano-Fujii; Yonson Ku; Seitetsu Yoon; Hak Hotta
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

5.  Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors.

Authors:  A Shrivastava; S K Manna; R Ray; B B Aggarwal
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

6.  Inhibition of Annexin A2 gene transcription is a promising molecular target for hepatoma cell proliferation and metastasis.

Authors:  Zhizhen Dong; Min Yao; Haijian Zhang; Li Wang; Hua Huang; Meijuan Yan; Wei Wu; Dengfu Yao
Journal:  Oncol Lett       Date:  2013-11-06       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.